



Module 3 – May 12<sup>th</sup>, 2021

### Guest speakers (in order of appearance)

#### Dr Nathalie Strub-Wourgaft, DNDi



Dr Nathalie Strub-Wourgaft is part of the DNDi team since 2009, and holds over 35 years of experience in R&D and public health since the past 11 years. Dr Strub-Wourgaft is currently the Director of Neglected Tropical Diseases (NTDs) and acting ANTICOV Lead at DNDi. She provides strategic and technical oversight to a wide portfolio of R&D and access plans for therapeutic areas covering sleeping sickness, Chagas disease, cutaneous and visceral leishmaniasis, filarial diseases, mycetoma, and COVID-19, answering unmet medical needs for neglected populations.

Before her time at DNDi, she served as Clinical Development Director at Trophos, and held many related roles with Pfizer, Lundbeck, Asperva, and CROs.

Dr Strub-Wourgaft graduated as Medical Doctor from Necker Hospital, Université René Descartes in Paris in 1983.

**Drugs for Neglected Diseases initiative, DNDi**, is an international non-profit organisation that engages in the discovery, development and delivery of safe, effective, and affordable treatments for neglected populations. In initiating and coordinating drug R&D projects in collaboration with different partners from academia, the public sector and the pharmaceutical industry, the bridge existing R&D gaps in essential drugs for neglected diseases. Since its inception in 2003, DNDi has developed 8 field-adapted and affordable treatments for 5 deadly diseases friendly – that have saved millions of lives.

#### Mathias Mondy, IVCC

Mathias is responsible for developing trustworthy relationships with the IVCC funders. He works to build their grant applications and ensure that IVCC are complying with the terms of their agreements. He is also responsible for tracking and reporting on product development supported by IVCC. His primary goal is to ensure the successful implementation of project plans so these new solutions can quickly be made available to communities affected by insect borne diseases. Mathias is also the Project Manager of the Attractive Targeted Sugar Bait (ATSB®) project. This project focuses on developing a mosquito bait which protects against outdoor malaria transmission.



Mathias graduated as an Agronomic Engineer from Agro Paris Tech and spent 17 years in the industry before joining IVCC, working for companies such as Rhône-Poulenc, Aventis and Bayer. At these organisations he held different responsibilities, including: product development, business intelligence, portfolio management, marketing, and stakeholder engagement. He later specialised in stakeholder engagement and advocacy in Europe, Asia and Africa.

Founded in 2005, the **Innovative Consortium Vector Control, IVCC**, a UK-registered charity, is the only PDP working on vector control. IVCC works with stakeholders to facilitate the development of novel and improved public health insecticides and formulations to combat the rapidly growing problem of insecticide resistance. IVCC brings together partners from industry, the public sector and academia to create new solutions to prevent malaria and other NTDs transmission.

### **Dr. Emma Hannay**



Dr Emma Hannay serves as FIND's Chief Access Officer, supporting FIND's efforts to expand access to effective diagnostic testing. She has been leading FIND's COVID response, including the creation of the ACT-Accelerator Diagnostics Partnership, co-convened by FIND and The Global Fund.

Emma is a public health doctor with a focus on global health strategy and delivery. Her work has been centred at a global level on organizational strategy in global health, and at a country level in implementing health system reforms in complex operating environments. In her previous role as Head of Health at Acasus, she helped design and lead the Pakistan Health Reforms Roadmaps, which improved primary care for more than 150 million people, and the DRC's Mashako Plan to increase immunization coverage for children.

Prior to joining Acasus, she was manager of the Market Dynamics Team at Unitaid in Geneva, and an Engagement Manager for McKinsey & Company based out of Dubai and Washington, DC. She holds a medical degree from the University of Auckland, New Zealand and a Master of Public Health from Harvard University.

The **Foundation for Innovative New Diagnostics, FIND**, is a global non-profit organisation that seeks to drive innovation in the development and delivery of simple-to-use diagnostics to combat major diseases that affect the world's poorest populations. They partner up with the public, private and non-profit actors, with whom they bridge R&D and access for 6 disease programmes. They bring in a deep technical and practical experience in a wide range of activities, such as product development, market analysis, they also generate evidence for regulators and policy-makers.

### **Anthony Man, Novartis**

Dr. Anthony Man, since 2017 Global Clinical Development Head, Communicable Diseases, Global Health Development Unit at Novartis Pharma in Basel, Switzerland, is a medically qualified professional with over 30 years of international drug development experience in the pharmaceutical and biotechnology industry. This includes previous significant roles in the development and approval of around 30 different new drugs in multiple therapeutic areas (including oncology) and senior executive management responsibilities in companies such as Novartis and Roche, among others.



Dr. Man joined Medigene's Supervisory Board in 2020 and is mandated until 2023. He is independent and does not hold essential positions besides the Supervisory Board mandate.

### **Claude Oeuvray, Merck**



Claude is the responsible for the development of the strategy and the clinical phases related to the Malaria pillar of the Merck Global Health Institute and supports the external financing approaches for the Institute.

Before joining Merck, Claude worked with MMV (Medicines for Malaria Venture) where he was responsible for the portfolio management and the fundraising strategy. Claude has a strong background and expertise in malaria drug and vaccine development. At MMV, he also co-lead the development of Pyramax<sup>®</sup> up to the successful submission of the dossier to EMA in 2010. He contributed to strengthen capacities in the participating clinical centres.

Prior to MMV, he developed the first seamless Phase IIb/III clinical study in malaria for Coartem D at Novartis and was involved in anti-viral drug development. In addition, Claude has several years of experience in vaccines research and immunology. He is co-inventor of a malaria vaccine, MSP3, and he holds a PhD in biology obtained at the Pasteur Institute and a master in management of innovation.

### **Rob Terry, TDR**

Rob Terry is the Manager for Research Policy at TDR (the Special Programme for Research and Training in Tropical Diseases) housed in WHO. Rob joined TDR in August 2013. His early career in research and development was in agriculture, including helping Palestinian farmers establish local seed production facilities where he started to build both scientific and policy expertise. He went on to positions at the Wellcome Trust and the Royal Society, one of the world's most distinguished research academies, where he had extensive experience formulating R&D strategy and policy. He joined WHO



in 2007 and managed the development and implementation of Organization's strategy on research for health. He is one of the lead authors of the 2013 World Health Report– Research for Universal Health Coverage and developed the concept for the WHO Observatory on Health R&D."I'm excited to be working in TDR," he says. The new strategy requires extensive networking, building partnerships and a multidisciplinary approach. I hope my own multi-disciplinary experience can add something of value to one of the most dedicated and committed teams I have worked with while at WHO."